Literature DB >> 30038442

New Medications in the Treatment of Hereditary Transthyretin Amyloidosis.

Scot Walker1.   

Abstract

Hereditary transthyretin amyloidosis is an inherited disorder that results in the gradual progressive deposit of abnormal protein called amyloid in the body's organs and tissues. There are currently no approved drugs to treat transthyretin amyloidosis, and patients may require liver transplantation for survival. There are a few drugs in development to treat hereditary transthyretin amyloidosis either by stabilizing the abnormal protein or by decreasing production of transthyretin. Both methods are being developed to slow progression of the disease.

Entities:  

Keywords:  drug information; formulary management / P & T; investigational drugs

Year:  2018        PMID: 30038442      PMCID: PMC6050879          DOI: 10.1177/0018578718779757

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  9 in total

1.  Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy.

Authors:  Laerke M Nelson; Luit Penninga; Kaare Sander; Peter B Hansen; Gerda E Villadsen; Allan Rasmussen; Finn Gustafsson
Journal:  Clin Transplant       Date:  2012-12-27       Impact factor: 2.863

2.  Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.

Authors:  Yoshiki Sekijima; Maria A Dendle; Jeffery W Kelly
Journal:  Amyloid       Date:  2006-12       Impact factor: 7.141

3.  Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.

Authors:  Denis Keohane; Jeffrey Schwartz; Balarama Gundapaneni; Michelle Stewart; Leslie Amass
Journal:  Amyloid       Date:  2017-04-10       Impact factor: 7.141

4.  Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation.

Authors:  Ayako Tsuchiya; Masahide Yazaki; Fuyuki Kametani; Yo-ichi Takei; Shu-ichi Ikeda
Journal:  Liver Transpl       Date:  2008-04       Impact factor: 5.799

5.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

Review 6.  Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges.

Authors:  Morie A Gertz
Journal:  Am J Manag Care       Date:  2017-06       Impact factor: 2.229

7.  Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and the Prospect of Bioengineering Autologous Liver Grafts.

Authors:  Dany Habka; David Mann; Ronald Landes; Alejandro Soto-Gutierrez
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 8.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

9.  Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.

Authors:  Márcia Waddington Cruz; Leslie Amass; Denis Keohane; Jeffrey Schwartz; Huihua Li; Balarama Gundapaneni
Journal:  Amyloid       Date:  2016-08-05       Impact factor: 7.141

  9 in total
  1 in total

Review 1.  RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.

Authors:  Sarah Bajan; Gyorgy Hutvagner
Journal:  Cells       Date:  2020-01-07       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.